🚀 The Infertility Treatment Market is Booming: Here’s Why Now is the Time to Invest! 🚀

The global infertility treatment market is in the midst of a powerful transformation, creating unique opportunities for businesses ready to innovate and grow. With the market projected to double from $1.9 billion in 2024 to $3.8 billion by 2034, the future is bright for this sector 🌟.

Why the Growth?
Tech Advancements 🌐: Cutting-edge technologies—like AI-driven embryo selection, time-lapse imaging, and enhanced fertility diagnostics—are making treatments more successful and accessible. This innovation is drawing more people than ever to fertility clinics.

Shifting Societal Attitudes 🌱: What was once stigmatized is now being openly discussed and embraced. High-profile voices and shifting norms are making fertility treatments mainstream, empowering couples to seek help early and confidently.

Demographic Changes 🌎: Career priorities, lifestyle changes, and later family planning are impacting fertility rates, particularly in developed countries. This trend is pushing demand for fertility solutions and driving the market.

Government & Institutional Support 💼: Countries like Germany are investing in reproductive health research, expanding the possibilities of fertility treatments and helping make them more affordable.

Regional Highlights 📊
North America & Europe: The U.S. and Germany are leading with steady growth, while rising healthcare innovation drives the market forward.
Asia-Pacific: India and China are showing phenomenal growth, with India expected to see an 8.3% CAGR thanks to a young, health-conscious demographic.
The Bottom Line
This market is fertile ground for businesses ready to embrace change, invest in tech, and support a growing number of individuals on their fertility journey. With society opening up, technology advancing, and demand surging, the question isn’t if you should join the movement—it’s how soon! 💡

#Healthcare #Innovation #InfertilityTreatment #BusinessGrowth #FutureOfHealthcare

Colorectal cancer prevalence in India

• India has the 3rd highest cases of colorectal cancer in the world and 10% of the total cancer cases in India are based on registered cases only.
• Colorectal Cancer is the 4th highest cancer in Men at a CAGR 10.6%.
• Estimated number of new cases 2020-2040 in India will be up by 57.5%.
• India’s mortality rate is the highest in the world due to late-stage detection of the disease.

Current Challenges in India

• There’s a significant lack of awareness about colorectal cancer in India, leading to late-stage diagnoses and poorer outcomes.
• Public health campaigns and educational initiatives are limited compared to other types of cancers.
• Rising incidence rates - among top ten cancers in India due to various factors, including lifestyle changes, dietary habits, and increasing life expectancy.
• Limited access to screening facilities
• High costs associated with screening facilities.
• Cultural and social stigmas.
Current and future colorectal cancer screening strategies
• Throughout the world, the most used approach for colorectal cancer screening is the faecal immunochemical test (FIT).
• Colonoscopy is the most common screening modality in the USA and is also used in many other regions, including, for example, parts of Germany and Poland.
• offering non-invasive tests as a screening option effectively improves adherence to screening.
• There are five blood tests currently being studied as a potential alternative to FIT and colonoscopy for CRC screening.
• Novel imaging tests, such as the colon capsule, mR colonography and the Ct capsule, are also undergoing active investigation.
• Recovery from deferred screening due to the CovID-19 pandemic will require the use of non-invasive screening options to help select patients for colonoscopy.

Innovative Early detection from Biosysion
Colocam DX - FIT Tube – self Test
ColoCam DX FIT Tube® -is most advanced non-invasive Fecal Immunochemical Test is reliable, accurate, and affordable. FIT colon cancer screening test is a proven and recommended colon cancer screening test used by doctors and hospitals worldwide – over-the-counter self-test kit. The ColoCam Tube® self-test is easy to perform in the comfort of your own home and results are ready within five minutes. With ColoCam Tube®, no prescription, doctor's visit, or mailing a sample back to a laboratory is required.

ColoCam DX - FIT DNA
 Colorectal cancer begins when cells in the intestine undergo genetic mutations. Tumour cells shed into the intestines. Stool samples can be examined for tumour DNA using PCR technology.
 Polymerase chain reaction (PCR) is used to rapidly make millions to billions of copies of a specific DNA sample and only requires a very small sample of DNA to amplify it large enough for detailed study.
 ColoCam DX® - FIT DNA utilizes proprietary methods to analyse the cell DNA for specific Tumour markers.
 ColoCam DX® - FIT DNA is designed to detect tumour DNA and detect 95% of colorectal cancer cases – often in the earliest stages of the disease. *
 Ease-of-use drives ongoing patient adherence as the ColoCam DX® - FIT DNA method requires very small samples compared to screening method.